[EN] GLUCAGON-LIKE PEPTIDE-1 RECEPTOR MODULATORS AND USES THEREOF [FR] MODULATEURS DU RÉCEPTEUR DU PEPTIDE-1 SIMILAIRE AU GLUCAGON ET LEURS UTILISATIONS
摘要:
Disclosed are compounds of formula I or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods related to agonists of glucagon-like peptide-1 receptor (GLP-1R). In particular, the compounds and compositions may be used to treat GLP-1R-related disorders and conditions, including, e.g., obesity, T2DM, NAFLD, NASH as disclosed herein.
[EN] GLUCAGON-LIKE PEPTIDE-1 RECEPTOR MODULATORS AND USES THEREOF [FR] MODULATEURS DU RÉCEPTEUR DU PEPTIDE-1 SIMILAIRE AU GLUCAGON ET LEURS UTILISATIONS
摘要:
Disclosed are compounds of formula I or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods related to agonists of glucagon-like peptide-1 receptor (GLP-1R). In particular, the compounds and compositions may be used to treat GLP-1R-related disorders and conditions, including, e.g., obesity, T2DM, NAFLD, NASH as disclosed herein.
[EN] GLUCAGON-LIKE PEPTIDE-1 RECEPTOR MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DU RÉCEPTEUR DU PEPTIDE-1 SIMILAIRE AU GLUCAGON ET LEURS UTILISATIONS
申请人:[en]HEPAGENE THERAPEUTICS (HK) LIMITED
公开号:WO2023001237A1
公开(公告)日:2023-01-26
Disclosed are compounds of formula I or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods related to agonists of glucagon-like peptide-1 receptor (GLP-1R). In particular, the compounds and compositions may be used to treat GLP-1R-related disorders and conditions, including, e.g., obesity, T2DM, NAFLD, NASH as disclosed herein.